Second Genome Advances Lead, Oral Small Molecule SGM-1019, Toward Clinical Investigation in NASH After Demonstrating Safety and Tolerability in Phase 1 Study

December 19, 2017, SOUTH SAN FRANCISCO, Calif., Dec 19, 2018

Read More

Second Genome Launches Study of the Relationship Between Microbiome and Central Nervous System in Autism Spectrum Disorders

October 3, 2017,

Fast-Track SBIR grant applied towards the development of a commercial platform for discovery and validation of key microbial metabolites linked to CNS disorders

Read More

Second Genome Named Technology Pioneer by World Economic Forum

June 4, 2017,

Read More